Reprogramming immune cells
restoring lives
Resetting the energy metabolism
of dysfunctional immune cells
to conquer disease

A breakthrough approach

for a broad range of LYSOSOMAL
and mitochondrial diseases

Tranquis Therapeutics, a trailblazing clinical-stage biopharmaceutical company, is developing a portfolio of small molecule drugs capable of reprogramming dysfunctional cells to restore normal cell homeostasis and function.

Our therapeutic candidates are master regulators of mitochondrial and lysosomal function. We have the potential to revolutionize the management of an entire range of CNS and non-CNS indications by modifying disease to improve millions of lives throughout the world.

Smart science

The expertise, innovation and capabilities to advance the treatment of immune-mediated and mitochondrial diseases

Promising pipeline

A portfolio of drug candidates in clinical and pre-clinical development—ready to transform a range of diseases

Compelling careers

Join our exciting, collaborative and passionate
workplace—driven to make a difference in patients’ lives